Clinical Trial Update: Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with paclitaxel in hormone receptor-positive metastatic breast cancer selected for high tumor mutational burden.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yonsei University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN